Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 12, 2023First-in-class ALTUVIIIO offers clinically proven highly effective bleed protection with once-weekly dosing for children with hemophilia A
-
Aug 24, 2023The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
-
May 5, 202317 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY® molecule in COPD and asthma
-
Apr 27, 2023
-
Mar 23, 2023First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo
-
Mar 18, 2023More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
-
Dec 21, 2022Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
-
Dec 2, 2022Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
-
Sep 28, 2022Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
-
Sep 19, 2022